Early Platelet Response To Dacogen May Predict MDS Patients’ Survival (EHA 2012)
Published: Jul 24, 2012 9:17 am
Myelodysplastic syndromes patients who achieve a platelet response by the end of the second cycle of Dacogen treatment are more likely to respond to Dacogen treatment and have better overall survival, according to a team of South Korean researchers.
These findings were presented at the 17th Congress of the European Hematology Association (EHA) held last month in The Netherlands.
According to the South Korean researchers, between 30 percent and 54 percent of myelodysplastic syndromes (MDS) patients treated with Dacogen (decitabine) respond to treatment, but there is currently no way to predict which patients will respond and how long they will survive.
The researchers therefore sought to identify factors that would predict response to Dacogen treatment and overall survival.
They retrospectively analyzed data from 100 MDS patients treated with Dacogen at the Samsung Medical Center in Seoul, South Korea, between August 2008 and August 2011.
All patients received Dacogen daily for the first five days of each 28-day treatment cycle. They completed a median of six treatment cycles.
The overall response rate was 58 percent. The median time to response was one treatment cycle.
After a median follow-up time of 12.5 months, the median overall survival was 17.7 months.
Higher-risk MDS patients who had improved blood cell counts survived longer than higher-risk patients who did not (22.5 months versus 16.7 months, respectively).
There was no difference in overall survival between lower-risk MDS patients who had improved blood cell counts versus those who did not.
In addition, there was no difference in overall survival between patients who achieved complete bone marrow response and those who did not.
The researchers found that experiencing increased platelet counts by the end of the second Dacogen cycle is a predictor of response to Dacogen and overall survival.
During the 708 total cycles of Dacogen administered to all the patients, there were 128 cases of fever that required treatment with antibiotics.
- Early Platelet Response To Vidaza Therapy May Predict Survival In MDS Patients
- Continued Vidaza Treatment Improves Outcomes For Lower-Risk MDS Patients (EHA 2012)
- Dacogen And Vidaza May Improve Survival Of MDS Patients With Monosomy 7 (EHA 2012)
- Study Confirms Dacogen Is Effective And Safe For Elderly MDS Patients (EHA 2011)
- Thrombopoietin Levels Influence Treatment Response And Survival In MDS Patients With Low Platelet Levels